Keywords: آگونیست بتا2 بلند مدت; Patient-reported outcomes; Health-related quality of life; Work and activity impairment; Asthma; Real-world; Fluticasone furoate/vilanterol; ACT; Asthma Control Test; ANCOVA; analysis of covariance; AQLQ (S); Standardized Asthma Quality of Life Questionna
مقالات ISI آگونیست بتا2 بلند مدت (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: آگونیست بتا2 بلند مدت; Asthma; Adult-onset; Asthma duration; Childhood-onset; Elderly; Inflammatory biomarker; ACQ; Asthma control questionnaire; AQLQ; Asthma quality of life questionnaire; ATS; American Thoracic Society; BMI; Body mass index; BTS; British Thoracic Society; CAP
Long-Acting Bronchodilator Initiation in COPD and the Risk of Adverse Cardiopulmonary Events
Keywords: آگونیست بتا2 بلند مدت; long-acting anticholinergic; long-acting β-agonists; community-acquired pneumonia; epidemiology; CPRD; Clinical Practice Research Datalink; HDPS; high-dimensional propensity score; HES; Hospital Episodes Statistics; HR; hazard ratio; ICS; inhaled cortico
Efficacy and safety comparison: Fluticasone furoate and fluticasone propionate, after step down from fluticasone furoate/vilanterol in Japanese patients with well-controlled asthma, a randomized trial
Keywords: آگونیست بتا2 بلند مدت; Asthma; Well-controlled asthma; Inhaled corticosteroid; Long-acting beta2-agonist; 'Step down' of asthma therapy; 'Step across' of asthma therapy;
Abediterol (LAS100977), a novel long-acting β2-agonist: Efficacy, safety and tolerability in persistent asthma
Keywords: آگونیست بتا2 بلند مدت; Asthma; Abediterol; Bronchodilation; LAS100977; Long-acting beta2-agonist; Safety;
Assessment of asthma control: The SERENA study
Keywords: آگونیست بتا2 بلند مدت; Uncontrolled asthma; International guidelines; Inhaled corticosteroids; Long-acting beta2-agonist; Asthma control test;
Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD
Keywords: آگونیست بتا2 بلند مدت; COPD; Long-acting beta2-agonist; Inhaled corticosteroid; Bronchodilator; Triple therapy;
Effect of fluticasone propionate/salmeterol (250/50 μg) or salmeterol (50 μg) on COPD exacerbations
Keywords: آگونیست بتا2 بلند مدت; Chronic obstructive pulmonary disease (COPD); Salmeterol; Fluticasone propionate; Long-acting beta2-agonist; Inhaled corticosteroid; ExacerbationsCOPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; FSC, fluticasone p
Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once daily
Keywords: آگونیست بتا2 بلند مدت; Asthma; Long-acting beta2-agonist; Inhaled corticosteroid; Fluticasone propionate; Salmeterol; Once daily
Outpatient Pharmacotherapy for Pediatric Asthma
Keywords: آگونیست بتا2 بلند مدت; FDA; Food and Drug Administration; FEV1; Forced expiratory volume in 1 second; ICS; Inhaled corticosteroid; LTM; Leukotriene modifier; LABA; Long-acting beta2-agonist; NAEPP; National Asthma Education and Prevention Program; PEF; Peak expiratory flow;
The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: An eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study
Keywords: آگونیست بتا2 بلند مدت; chronic obstructive pulmonary disease (COPD); salmeterol; fluticasone propionate; long-acting beta2-agonist; inhaled corticosteroid; anticholinergic; ipratropium; albuterol;